Mydecine Innovations Group Inc (MYCOF)

[Nosnibor]

Huge advancement and this lends tremendous credibility to Mydecine moving forward:
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine

Post published:August 18, 2021
Post category:Press Release

Agreement allowing work on numerous collaborative research initiatives in the coming years

DENVER, Aug. 18, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, with research to be led by Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, Dr. Matthew W. Johnson, Ph. D. The Johns Hopkins Behavioral Pharmacology Research Unit has extensive experience conducting clinical research related to therapeutic use of psychedelics.

Mydecine CEO Josh Bartch said, “We are excited to expand on the current work we are conducting with Dr. Matt Johnson and his team at JHU in regards to smoking cessation to include numerous other projects over the next five years. The researchers at JHU have proven their incredible depth of knowledge in the field.”

“The long-term potential of this research agreement is captivating for us here at Mydecine,” Chief Scientific Officer and Co-Founder of Mydecine, Rob Roscow, stated. “It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.”

This agreement allows Johns Hopkins University and Mydecine to further collaborate to advance research, on novel psychedelic therapies to treat mental health and addiction disorders.

“Despite the recent attention to opiate and dependance on other illicit substances, we sometimes forget about the incredible burden that nicotine dependence has on our societies,” said Dr. Rakesh Jetly, Chief Medical Officer, Mydecine. “According to the CDC, cigarette smoking is the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year. Despite all the public education and dire warnings, cigarette smoking remains one of the most difficult addiction to treat and contributes to more deaths than all the other substances combined, making research like this vital.”

About Mydecine Innovations Group
Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.